GlassScriptPhysician profile
John B Kelly
NPI 1407855315
$12,929.08
in general payments reported to CMS, 2019-2025
39 companies · $9,946 in 2025
The $9,946 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $315 · 2021: $284 · 2022: $452 · 2023: $939 · 2024: $854 · 2025: $9,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,588 · Food and Beverage: $3,036 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,587.50 |
| Food and Beverage | $3,035.66 |
| Education | $116.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $9,430.60 | 2023-2025 | |
| Abbvie INC. | $446.94 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $232.10 | 2022-2024 | Soliris, Ultomiris |
| Ucb, INC. | $205.13 | 2023-2025 | Fintepla, Briviact |
| Emd Serono, INC. | $202.50 | 2023-2025 | Mavenclad |
| Genzyme Corporation | $196.04 | 2020-2025 | |
| Biogen, INC. | $192.06 | 2023-2025 | Vumerity, Leqembi, Tysabri |
| Pfizer INC. | $187.99 | 2023 | |
| Sk Life Science, INC. | $177.92 | 2022-2024 | Xcopri |
| Neurocrine Biosciences, INC. | $131.48 | 2020-2025 | Ingrezza |
| Genentech USA, INC. | $130.80 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.69 | 2020-2021 | |
| Lundbeck LLC | $105.49 | 2020-2024 | Vyepti |
| Eisai INC. | $87.87 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $87.78 | 2019-2024 | Daybue |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.